@FierceMedDev: Illumina's Jay Flatley brought sequencing to another level in 2013--the $1000 genome is now a reality. Report | Follow @FierceMedDev
@MarkHFierce: Amedica's IPO is going steadily. Stock at $6.19 as of 10:56 A.M. Moderately higher. Story | Follow @MarkHFierce
@MichaelGFierce: CalTech engineers have created an antibody carrier that could prevent intravaginal HIV infection. Not a vaccine... More from FierceDrugDelivery | Follow @MichaelGFierce
@EmilyWFierce: "Musical hallucinations" give scientists clues about brain function, hearing loss. Article | Follow @EmilyWFierce
> AtriCure ($ATRC) has priced its previously announced underwritten public offering. The atrial fibrillation medical device company, along with selling stockholders, plans to offer 4.2 million shares of common stock at $19.25 per share. Item
> Spain's Neuroelectrics, a maker of neurostimulation and brain monitoring devices, has opened its first U.S. office at the Cambridge Innovation Center in Cambridge, MA. Item
> Cardiac diagnostics maker Cambridge Heart ($CAMH) is winding down operations and has auctioned off assets to pay creditors. Story
> A fast-moving winter storm forced the cancelation of Staar Surgical's ($STAA) meeting before the FDA Ophthalmic Devices Panel, which had been scheduled for Feb. 14. Staar is seeking a PMA supplement approval for its Visian Toric Implantable Collamer Lens. Item
> Diagnostic test-kit developer Corgenix Medical said that its revenue and net income increased during its fiscal 2014 second quarter. Item
> Scotland's Calcivis, a medical device company focused on tooth decay, won a CE mark for an imaging system designed to perform ultra-precise detection of tooth decay. Item
Biotech News
@FierceBiotech: Like him or not, Myriad Genetics' Peter Meldrum helped make predictive cancer testing viable. Profile | Follow @FierceBiotech
@JohnCFierce: Who's influential in biopharma? (ICYMI) Report | Follow @JohnCFierce
@DamianFierce: FDA rejects Durect's pitch to market post-operative pain therapy. More | Follow @DamianFierce
@EmilyMFierce: GlaxoSmithKline joins $115M antibiotics development initiative. Story via FierceBiotech Research | Follow @EmilyMFierce
> Novartis CEO Jimenez looking for new places to hatchet blockbuster R&D budget. News
> Biotech IPOs roll on with Concert's $84M aria. Article
> FDA panel pillories The Medicines Co.'s clot-fighting cangrelor. More
Pharma News
@FiercePharma: More than 2,000 Pradaxa patients are suing Boehringer over severe or fatal bleeding. More | Follow @FiercePharma
@TracyStaton: Our best-read feature every year: The most influential people in biopharma today. Report | Follow @TracyStaton
@EricPFierce: It's 1 thing for an API seller to have poor quality controls, but FDA says it's a real problem to have none. Story | Follow @EricPFierce
@CarlyHFierce: Merck consumer-health deal heats up with $10B-plus bids expected soon. News | Follow @CarlyHFierce
> Antitrust watchdogs come down on Pfizer for Lipitor dealmaking. Story
> Boehringer says it's fighting 2,000 lawsuits over Pradaxa safety. Article
> Merck consumer-health deal heats up with $10B-plus bids expected soon. News
Pharma Manufacturing News
> Congress wants more info about the quality of foreign-made generics. Story
> 2 Hospira plants improve their FDA standing as improvements kick in. Article
> Irish Regeneron plant to produce tax benefits as well as drugs. Story
> Catalent to expand in U.S. and add 230 jobs to its Kansas City operation. News
> The FDA slams a Hong Kong API for the sorry state of its quality controls. Story
> New plants in Middle East are a testament to the region's emerging market status. Item
Vaccines News
> Quadrivalent flu vaccines drive surge in sales at AstraZeneca, GSK and Sanofi. Earnings
> The President's Cancer Panel is pushing for increased use of Merck's and GSK's HPV vaccines. News
> Crowdfunded HIV project draws criticism from scientists. Story
> CDC: Adult vaccination rates are still well below targets. Article
> The U.S. flu season is slowly winding down after hitting some states hard. Story
> Global measles deaths have dropped 78% since 2000. Brief